Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.77 |
| ▸ | ITGAV | P06756 | 12/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461777 | 0.91 | ITGB3 (0.65) | ITGB3ITGA2BITGAV | |
| SCHEMBL7462037 | 0.91 | ITGB3 (0.64) | ITGB3ITGA2BITGAV | |
| SCHEMBL7464434 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BITGAV | |
| SCHEMBL7052283 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BITGAV | |
| SCHEMBL7046671 | 0.87 | ITGB3 (1.00) | ITGB3ITGA2BITGAV | |
| SCHEMBL30856544 | 0.87 | ITGB3 (1.00) | ITGB3ITGA2BITGAV | |
| SCHEMBL7474804 | 0.87 | ITGB3 (0.60) | ITGB3ITGA2BITGAV | |
| SCHEMBL6500800 | 0.87 | ITGB3 (0.64) | ITGB3ITGA2BITGAV | |
| SCHEMBL6505606 | 0.87 | ITGB3 (0.64) | ITGB3ITGA2BITGAV | |
| SCHEMBL7466752 | 0.85 | ITGB3 (0.72) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | claimed |
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGA2B 7/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.